JWCTF (JW (Cayman) Therapeutics Co) Asset Turnover: 0.15 (As of Dec. 2025)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
30 GF Score
Price $0.24
GF Value $0.64
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Asset Turnover?

JW (Cayman) Therapeutics Co JWCTF 30 Asset Turnover is 0.15 as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 30/100 and a GF Value™ of $0.64 (Possible Value Trap). The stock has 3 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. JW (Cayman) Therapeutics Co's Revenue for the six months ended in Dec. 2025 was $25.17 Mil. JW (Cayman) Therapeutics Co's Total Assets for the quarter that ended in Dec. 2025 was $168.90 Mil. Therefore, JW (Cayman) Therapeutics Co's Asset Turnover for the quarter that ended in Dec. 2025 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. JW (Cayman) Therapeutics Co's annualized ROE % for the quarter that ended in Dec. 2025 was -79.59%. It is also linked to ROA % through Du Pont Formula. JW (Cayman) Therapeutics Co's annualized ROA % for the quarter that ended in Dec. 2025 was -48.42%.


JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

JW (Cayman) Therapeutics Co's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-81.788/102.759
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-81.788 / 50.348)*(50.348 / 168.9015)*(168.9015/ 102.759)
=Net Margin %*Asset Turnover*Equity Multiplier
=-162.45 %*0.2981*1.6437
=ROA %*Equity Multiplier
=-48.42 %*1.6437
=-79.59 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

JW (Cayman) Therapeutics Co's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-81.788/168.9015
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-81.788 / 50.348)*(50.348 / 168.9015)
=Net Margin %*Asset Turnover
=-162.45 %*0.2981
=-48.42 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


JW (Cayman) Therapeutics Co Asset Turnover Related Terms


JW (Cayman) Therapeutics Co Asset Turnover Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Asset Turnover Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial 0.01 0.05 0.07 0.08 0.22

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.07 0.15

JWCTF vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Asset Turnover falls into.


JWCTF
30GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

JW (Cayman) Therapeutics Co's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=40.273/( (230.797+140.12)/ 2 )
=40.273/185.4585
=0.22

JW (Cayman) Therapeutics Co's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=25.174/( (197.683+140.12)/ 2 )
=25.174/168.9015
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.15 mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Asset Turnover of 0.15 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on JW (Cayman) Therapeutics Co and its competitors.
Is JW (Cayman) Therapeutics Co's Asset Turnover too high?
JW (Cayman) Therapeutics Co's current Asset Turnover is 0.15. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Asset Turnover compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's Asset Turnover of 0.15 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current Asset Turnover is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.64, compared to a current price of $0.24 — trading 62.9% below its estimated fair value. The current Asset Turnover is 0.15. JW (Cayman) Therapeutics Co's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Asset Turnover is 0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.24 is trading 62.9% below its estimated GF Value™ of $0.64. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Asset Turnover: 0.15
  • GF Value™: $0.64 vs. price of $0.24 (62.9% below fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
30GF Score

Get the complete analysis for JWCTF

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.24
Price
$0.64
GF Value